Melt Pharmaceuticals’ MELT-300 Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study
Melt Pharmaceuticals announced topline results of its phase 2 pivotal efficacy and safety study for its lead product candidate, MELT-300, a sublingual, needle- and opioid-free patented formulation for procedural sedation during cataract surgery. Based on the outcome of the MELT-300 data, the company intends to request a meeting with the FDA to discuss the results of this study and the continued clinical development of MELT-300.
MELT-300 combines fixed doses of midazolam (3mg) and ketamine (50mg) in one rapidly dissolving tablet (RDT) that is administered sublingually for procedural sedation during cataract surgery. MELT 300 utilizes Catalent Inc.’s proprietary fast-dissolving Zydis delivery technology to rapidly dissolve the tablet for absorption across the very thin sublingual mucosa.
The factorial-designed, randomized, double-blind, placebo-controlled, parallel-cohort phase 2 study was designed to evaluate the efficacy and safety of MELT-300 and the contribution of midazolam and ketamine components to sedation and intraoperative ocular analgesia in subjects undergoing cataract surgery. The trial compared MELT-300 against placebo alone, sublingually delivered midazolam alone, and sublingually delivered ketamine alone, with two independent primary efficacy endpoints: (a) appropriate cataract surgery sedation using a validated sedation scale (Ramsay Sedation Scale), or (b) the management of intraoperative pain during the cataract surgery. The study was conducted at nine sites and enrolled over 300 subjects.
“We are extremely pleased with the robust sedation efficacy from our pivotal phase 2 study of MELT 300,” said Larry Dillaha, MD, CEO of Melt Pharmaceuticals. “The clear, critical, and positive findings for our procedural sedation primary endpoint allow us to confidently proceed with the development of this non-IV option for cataract surgery. We believe the commercial appeal for offering patients and physicians the ability to achieve adequate sedation without the need to start an IV is an extremely attractive option for the nearly 5 million cataract surgeries performed every year in the United States and the more than 20 million cataract surgeries performed around the world each year.”
MELT-300 co-inventor, Melt Pharmaceuticals board member, and ophthalmologist John Berdahl, MD, commented, “The MELT-300 data for procedural sedation is extraordinary and promises to catalyze a shift in the sedation paradigm for cataract surgery in the United States and around the world. In particular, the data demonstrating that preoperative sublingual administration of MELT-300 was superior to midazolam has important implications for the daily workflow of the surgical team and most importantly the patient experience. I am excited beyond measure to see MELT-300 advance and, in time, become a candidate for FDA approval.”
Dr. Dillaha continued, “We intend to leverage the demonstrable synergy between the components of MELT-300 to fortify an already strong domestic and international patent portfolio so that in the future, we can develop, consistent with our vision, procedural sedation solutions for the approximately 100+ million annual procedures our technology may impact.”